NCT07488078

Brief Summary

The goal of this clinical trial is to learn whether giving less intravenous (IV) fluid (restrictive administration) after surgery is as effective as giving more IV fluid (liberal administration) in maintaining body stability (homeostasis) among adults undergoing laparoscopic gallbladder removal (cholecystectomy). The main questions it aims to answer are: Does restrictive IV fluid administration maintain stable blood pressure, heart rate, and urine output after laparoscopic cholecystectomy? Are there any differences in postoperative recovery or complications between restrictive and liberal fluid regimens? Researchers will compare patients receiving liberal IV fluid administration with those receiving restrictive IV fluid administration to see if both methods maintain similar postoperative homeostasis and recovery outcomes. Participants will: Be adults aged 18-60 years (ASA class I-II) undergoing elective laparoscopic cholecystectomy. Be randomly assigned to one of two groups: Group A: Liberal IV fluid administration for 6 hours after surgery. Group B: Restrictive IV fluid administration for 6 hours after surgery. Have their vital signs (pulse, blood pressure, mean arterial pressure) and urine output recorded at multiple time points after surgery (immediate, 3, 6, 12, and 24 hours).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
380

participants targeted

Target at P75+ for phase_1

Timeline
2mo left

Started Dec 2025

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress73%
Dec 2025Jul 2026

Study Start

First participant enrolled

December 1, 2025

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

December 5, 2025

Completed
4 months until next milestone

First Posted

Study publicly available on registry

March 23, 2026

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 28, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 28, 2026

Last Updated

March 23, 2026

Status Verified

March 1, 2026

Enrollment Period

8 months

First QC Date

December 5, 2025

Last Update Submit

March 17, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Mean Systolic Blood Pressure

    Mean systolic blood pressure at preoperative and 3,6, 12 and 24 hours post operatively

    Day 1

Secondary Outcomes (3)

  • Mean Pulse Rate Per Minute

    Day 1

  • Mean Diastolic Blood Pressure

    Day 1

  • Mean Pulse Pressure

    Day 1

Study Arms (2)

Liberal Fluid Administration

ACTIVE COMPARATOR

1000ml iv fluid

Drug: Lactated Ringer 1000ml

Restricted Fluid Administration

EXPERIMENTAL

500ml iv fluid

Drug: Lactated Ringer 500ml

Interventions

500ml ringer lactate perioperatively given in laparoscopic cholecystectomy patients as compared to traditional 1000ml fluid

Restricted Fluid Administration

1000ml iv fluid given perioperatively in laparoscopic cholecystectomy

Liberal Fluid Administration

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • All patients undergoing elective cholecystectomy
  • Age : 18-60 years
  • All genders
  • ASA class 1 and 2

You may not qualify if:

  • History of previous laparotomy
  • Perforated gall bladder
  • Duration of surgery more than 3 hours
  • More than 100ml intra operative blood loss

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

King Edward Medical University Lahore / Mayo Hospital Lahore

Lahore, Punjab Province, 54000, Pakistan

RECRUITING

MeSH Terms

Interventions

Ringer's Lactate

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 5, 2025

First Posted

March 23, 2026

Study Start

December 1, 2025

Primary Completion (Estimated)

July 28, 2026

Study Completion (Estimated)

July 28, 2026

Last Updated

March 23, 2026

Record last verified: 2026-03

Locations